Brought to you by 
Ventana to create a companion diagnostic for Millennium/Seattle Genetics' Adcetris
30 Apr 2012
Executive Summary
Roche’s cancer diagnostics division Ventana Medical Systems Inc. has agreed to develop, manufacture, and sell a molecular companion diagnostic that would be used in the treatment planning for Adcetris (brentuximab vedotin), a lymphoma therapy developed by Seattle Genetics Inc. and Millennium: The Takeda Oncology Co.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com